SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

XL092

Item No. 37749

CAS Registry No.:	2367004-54-2
Formal Name:	N-(4-fluorophenyl)-N′-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-1,1-cyclopropanedicarboxamide
Synonym:	Zanzalintinib
MF:	$C_{29}H_{25}FN_4O_5$
FW:	528.5
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

XL092 is supplied as a solid. A stock solution may be made by dissolving the XL092 in the solvent of choice, which should be purged with an inert gas. XL092 is soluble in DMSO.

Description

XL092 is a multi-kinase inhibitor.[1] It selectively inhibits the receptor tyrosine kinases (RTKs) MET, VEGFR2, Axl, and Mer (IC_{50}s = 3, 15, 5.8, and 0.6 nM, respectively) over serine/threonine kinases for which it has no activity, but does inhibit 28 other RTKs with IC_{50} values ranging from 3 to 54 nM, as well as additional kinases by greater than 70% at 1 µM. XL092 inhibits the proliferation of SNU-5 human gastric carcinoma cells (IC_{50} = 98.9 nM), which highly express MET, and human umbilical vein endothelial cells (HUVECs; IC_{50} = 10.4 nM). It reduces tumor volume and intratumoral MET phosphorylation in NCI H441 human lung cancer and SNU-5 mouse xenograft models when administered at doses of 3 and 10 mg/kg. XL092 (30 mg/kg) increases the number of peripheral B cells and $CD4^+$ T cells, and decreases the number of peripheral myeloid cells, in an MC-38 syngeneic mouse model of colon carcinoma, indicating a conversion to an immune-permissive tumor microenvironment.

Reference

1. Hsu, J., Chong, C., Serrill, J., *et al.* Preclinical characterization of XL092, a novel receptor tyrosine kinase inhibitor of MET, VEGFR2, AXL, and MER. *Mol. Cancer Ther.* **22(2),** 179-191 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM